"The chronic oral toxicity of propiverine hydrochloride (P-4), a new anti-pollakiuria agent, was studied in beagle dogs. Groups of 6 males and 6 females were treated with P-4 at doses of 0, 0.3, 1, 3, 9 mg/kg/day for one year and thereafter 2 animals of both sexes in each group were placed on withdrawal for one month."
Insmed's dog toxicity study was initiated last April. If it was initiated during the first week in April, the process of data collection and analysis from the dogs which didn't participate in the recovery phase would presumably have started about six weeks ago.
Would that allow sufficient time for data to leak out?
Fud, it won't leak. Not only that, Insmed's not going to even release the data IMO. It will simply be used in the safety profile labelling of Arikace. IMO, the rat study data was sufficiently addressed with the FDA to allow human trials to go forward and results of these trials are the real indicator for share price appreciation. And now we know that patients are continuing treatment when the trial is ended in very high numbers. That's a leak with value, and it came from Lewis himself!